Fig. 4: FAKi treatment leads to partial improved blood glucose homeostasis and increased β-cell mass in mice following near total ablation of β-cells.
From: Acinar to β-like cell conversion through inhibition of focal adhesion kinase
a A schematic representation of high-dose STZ-induced diabetes and FAKi treatment in wild-type mice. b, c Weekly measurements of the body weight (b) or the average random BG (c) in the 4 cohorts, *p ≤ 0.05 refers to multiple comparison between STZ+vehicle or STZ+FAKi treated mice. Random blood glucose was checked daily at the same time to calculate the average weekly BG in (c). The timepoints for STZ treatment or insulin pellet insertion are indicated by pink (STZ) or green (insulin) arrowheads in (c). d, e Graph for glucose tolerance test (d) and area under the curve (e) performed on the four indicated cohorts (n = 6 for STZ+FAKi), 5 for STZ+Vehicle, 4 for Saline+FAKi, and 5 for Saline+Vehicle group). f Immunofluorescent imaging for detection of insulin and glucagon of representative islets obtained from the indicated cohorts (n = 3 per group). g β-cell mass quantification in the indicated cohorts (n = 3 per group). h Immunofluorescent imaging for detection of Tomato, insulin and BrdU in STZ+vehicle or STZ+FAKi ElaCreERT2,R26Tom treated mice showed no differences in proliferation between the cohorts (n = 3 per group). i Quantification of ins+/BrdU+ cells in ElaCreERT2,R26Tom mice treated with STZ+vehicle or STZ+FAKi (n = 3 per group). Data is presented as mean ± SD. Statistical analysis was performed using two-way ANOVA (b, c), one-way ANOVA in (e, g) followed by Holm-Sidak for multiple comparisons, and unpaired two-tailed t-test (i). *p ≤ 0.05, ***p ≤ 0.001, ****p ≤ 0.0001. Scale bar = 20 μm. Source data are provided as a Source data file.
